Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion
Proposed combination enhances Pfizer’s position as a leading company in Oncology
Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio
Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030
Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today
NEW YORK & BOTHELL, Wash.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction. Continue reading →